Remove 2006 Remove Pharmaceuticals Remove Pharmacokinetics
article thumbnail

Gepirone

New Drug Approvals

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] Jump up to: a b c d e “Gepirone – Fabre-Kramer Pharmaceuticals” AdisInsight. 1] It is taken orally. [1] 1] Gepirone acts as a partial agonist of the serotonin 5-HT 1A receptor. [1]

FDA 62
article thumbnail

Game-changing pan-TEAD inhibitor for solid tumours

Drug Target Review

What are the preclinical characteristics of ISM6331, including its efficacy, safety profile, and drug metabolism and pharmacokinetics (DMPK) properties? Prior to founding Insilico, Alex worked in senior roles at ATI Technologies (a GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, and the Biogerontology Research Foundation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

The Pharma Data

As part of the comprehensive submission package to the European Marketing Authorization, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50 mg/mL 2 with the 100 mg/mL (HCF). About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

article thumbnail

Metabolism of five membered nitrogen containing heterocycles

Metabolite Tales Blog

2006 , 34, 145-51 [link] 3 Drug Metab. 2018, 26, 965-972 [link] 4a Pharmaceutics, 2022, 14, 1001 [link] 5 Phys. 2006, 34,748-755 [link] 15 Drug Metab. 2010, 75, 9, 3141–3143 [link] 22 Clin Pharmacokinet. 2002, 15, 3, 269–299 [link] 2 Chem. 2017, 30, 1, 13–37 [link] 2a Drug Metab. 1980, 8, 34-38 [link] 4 J. Food Drug Anal.

article thumbnail

TACACICLIB, AUR-102, AURIGENE

New Drug Approvals

2006 Mar 1; 20(5):601-12, 2006), in contrast with CDK9, which phosphorylates both Ser-2 and Ser-5 of the CTD heptad (Pinhero et al., For drug development, it is typically advantageous to employ individual stereoisomers as they exhibit marked differences in pharmacodynamic, pharmacokinetic, and toxicological properties.

article thumbnail

Analysis Life Sciences Thank You FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity

Agency IQ

In 2006, the ICH released its S8 Guideline on Immunotoxicity Studies for Human Pharmaceuticals , which provided recommendations on how companies should test pharmaceuticals for “unintended immunosuppression and immunoenhancement, excluding allergenicity or drug-specific autoimmunity.”

FDA 40
article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. 12 , 2955–2960 (2006). 9 Others, like psymberin, have been used as ADC payloads, with a β-glucuronide linker to target CD-30-positive and CD-70-positive malignancies.